MUNDIPHARMA
16.1.2020 15:00:04 CET | Business Wire | Press release
Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO, Raman Singh. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments,” he added.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. For more information please visit: www.mundipharma.com.sg .
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter , LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005483/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Telekom Srbija Group Announces Platinum Sponsorship of EXPO 2027 Belgrade20.2.2026 12:32:00 CET | Press release
Telekom Srbija to power EXPO 2027 and unveil dedicated pavilion showcasing its technology ecosystem Telekom Srbija Group today announced its Platinum Sponsorship of EXPO 2027 Belgrade, marking a major milestone in the company’s continued leadership in digital innovation and infrastructure across the region. As a Platinum Sponsor, Telekom Srbija will play a central role in delivering the digital backbone of EXPO 2027, powering connectivity and enabling the state-of-the-art technological infrastructure that will support one of the largest international events ever hosted in Serbia. EXPO 2027 represents a defining moment for Belgrade, Serbia, and the wider region. For Telekom Srbija, the partnership is both a strategic commitment and a landmark opportunity to demonstrate the full strength of its technological ecosystem on a global stage. Telekom Srbija will also host its own pavilion at EXPO 2027, creating an immersive space to showcase its technologies, innovation platforms and future-fa
Axelspace Secures Japan Ministry of Defense Satellite Constellation Project20.2.2026 12:01:00 CET | Press release
As an optical imagery provider, Axelspace has entered into a contract for the acquisition of image data Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that, for the purpose of carrying out the Ministry of Defense’s satellite constellation project, it has entered into a contract with Tri-Sat Constellation Co., Ltd. and Mitsui Bussan Aerospace Co., Ltd. for acquisition of optical imagery data. Tri-Sat Constellation Co., Ltd. is a special purpose company (SPC) established by Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, and Mitsui & Co., Ltd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220758297/en/ An imagery of satellite constellation © the Ministry of Defense The Ministry of Defense’s satellite constellation project was awarded to a consortium comprising Mitsubishi Electric Corporation, S
Sai Life Sciences to Recruit 700+ Professionals in FY2720.2.2026 10:09:00 CET | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220711675/en/ Integrated R&D Campus, Sai Life Sciences, Hyderabad, India The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others. A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally,
Balmain Beauty Introduces Destin de Balmain: A New Prestige Fragrance20.2.2026 08:30:00 CET | Press release
Balmain Beauty unveils Destin de Balmain, its debut prestige fragrance. The new feminine fragrance is a bold, floral fruity eau de parfum that captures the unstoppable energy of the Balmain woman: independent, youthful, and unapologetic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219851364/en/ Destin de Balmain (Photo Credit: Balmain Beauty) THE STORY: LIVE YOUR DESTINY Destin de Balmain is destiny you hold in your hands, a journey of optimism and infinite possibilities. The refillable fragrance unites those who express themselves without rules or expectations. Inspired by the Parisian House’s savoir-faire and modern pulse, the daring fragrance celebrates choosing your path and living your destiny. “Destin de Balmain features a joyful, optimistic spark of ripe strawberry,” said Quentin Bisch, Perfumer. “The fruit’s juicy vivacity brings bright, elevated sweetness to the composition. Notes of peony further convey the f
SOLUM and EWQ Announce Strategic Partnership Expansion at EuroShop to Advance Integrated In-Store Digital Communication20.2.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070), a global retail solutions provider, and EWQ, a leading retail infrastructure innovator, have announced the expansion of their strategic partnership to accelerate integrated in-store digital communication. Building on their existing collaboration, the two companies will deepen technology integration and commercial cooperation to deliver a unified platform connecting Electronic Shelf Labels (ESL), large-format E-Paper displays, and digital signage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219422813/en/ ScanToPair enables seamless pairing of products and digital signage through simple barcode scanning, automatically synchronizing product and pricing information. (Image: SOLUM) A central focus of the expanded partnership is the integration of EWQ’s ScanToPair solution with SOLUM’s Newton ESL and digital signage. ScanToPair enables seamless pairing of products and digital signage through simple bar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom